Third clinical test on SK drug starts

Published: 2013-06-11 06:58:00

Updated: 2013-06-11 06:58:00

After proving its safety and efficacy in the first round, SK Chemicals announced Sunday that its business partner CSL Limited, a biopharmaceutical company headquartered in Melbourne, Australia, has started Phase III clinical trial for “NBP601,” a drug for treatment of hemophilia A exclusively dev...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK